🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,146 results for “Yung” Clear

  1. 0.9% sodium chloride

    The First People's Hospital of Lianyungang

    Kidney Disease, Chronic

    phase 2 small molecule active

    1 trial

  2. 177Lu-DOTA-EB-FAPI radionuclide therapy

    The First People's Hospital of Lianyungang

    Refractory Solid Tumor

    phase 2 small molecule completed

    1 trial

  3. 18F-92

    The First People's Hospital of Lianyungang

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  4. 2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy

    The First People's Hospital of Lianyungang

    Cervical Cancer Stage IVA

    phase 2 other active

    1 trial

  5. 225Ac-LNC1011

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  6. 3D hypoxia-preconditioned UC-MSC group

    The First People's Hospital of Lianyungang

    Severe Aplastic Anemia (SAA)

    phase 2 small molecule active

    1 trial

  7. 68Ga-DOTATATE and 68Ga-FAPI

    The First People's Hospital of Lianyungang

    Tumor Positron-Emission Tomography

    phase 2 small molecule completed

    1 trial

  8. 68Ga-FAP-CHX

    The First People's Hospital of Lianyungang

    Tumor

    phase 2 small molecule active

    1 trial

  9. 68Ga-G21

    The First People's Hospital of Lianyungang

    Prostate Cancer (Adenocarcinoma)

    phase 2 small molecule active

    1 trial

  10. 68Ga-NY104 PET/CT

    The First People's Hospital of Lianyungang

    Clear Cell Renal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  11. AK104, nab-paclitaxel, carboplatin

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  12. AK105 and anlotinib

    The First People's Hospital of Lianyungang

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  13. ASC22

    The First People's Hospital of Lianyungang

    Chronic Hepatitis b

    phase 2 small molecule completed

    1 trial

  14. Abatacept s.c.

    The First People's Hospital of Lianyungang

    Abatacept

    phase 2 small molecule active

    1 trial

  15. Absorbable and moldable skull base support plate

    The First People's Hospital of Lianyungang

    Sellar Tumor

    phase 2 other active

    1 trial

  16. Ad-HGF

    The First People's Hospital of Lianyungang

    Myocardial Infarction

    phase 2 small molecule active

    1 trial

  17. Adebellizumab

    The First People's Hospital of Lianyungang

    Resectable Lung Non-Small Cell Carcinoma

    phase 2 small molecule active

    1 trial

  18. Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  19. Adebrelimab+Albumin paclitaxel +Cisplatin

    The First People's Hospital of Lianyungang

    Locally Advanced Hypopharyngeal Cancer

    phase 2 small molecule active

    1 trial

  20. Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib

    The First People's Hospital of Lianyungang

    Platinum-sensitive Relapsed Ovarian Cancer

    phase 2 small molecule active

    1 trial

  21. All-trans Retinoic Acid in combination with the KPD Regimen

    The First People's Hospital of Lianyungang

    Multiple Myeloma in Relapse

    phase 2 small molecule active

    1 trial

  22. Almonertinib

    The First People's Hospital of Lianyungang

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  23. Almonertinib

    The First People's Hospital of Lianyungang

    EGFR Positive Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  24. Ametinib combined with bevacizumab

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources